Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention for non-ST-segment elevation myocardial infarction: results of the SELECT-ACS trial - Tardif, JC (J Am Coll Cardiol, 2013)
et al.